logo     small logo upcfbih    

powered by social2s

Semir Vranić juni 2017

Semir Vranić, M.D., Ph.D.
Assistant Professor of Pathology, UICC Fellow

Affiliation

 Degrees

  • M.D. degree, University of Sarajevo School of Medicine (2004)
  • UICC Lifetime Fellow, Creighton University School of Medicine, Omaha, Nebraska, United States of America (2010)
  • Pathologist, Clinical Center of the University of Sarajevo (2011)
  • Ph.D. degree, Zagreb University School of Medicine (2012)
  • Research associate, Zagreb University School of Medicine (2013)
  • Assistant Professor of Pathology, University of Sarajevo School of Medicine (2016-2017)
  • Assistant Professor of Pathology, College of Medicine, Qatar University (2017)

Post-Doctoral Training

  • Department of Pathology, Creighton University School of Medicine, Omaha, Nebraska, United States of America (2008-2009)
  • Department of Medical Sciences, University of Turin, Italy (2012-2013)

Research Interests

  • Breast cancer pathology (special types of breast carcinomas)
  • Hereditary cancer syndromes
  • Genitourinary pathology
  • Molecular pathology of rare tumors and molecular diagnostics (precision medicine)
  • Surgical pathology (diagnostics)
  • Scientific publishing, journal editing

Administrative/Organizational Experience/Peer-review/

  • Organizer and course coordinator of the Bryan Warren School of Pathology (earlier: Bosnian British School of Pathology) (collaboration with British Division of the International Academy of Pathology/BDIAP/) (since 2007-)
  • President of the Association of Pathologists and Cytologists of Federation of Bosnia and Herzegovina (2015-2017), link: http://www.bosnianpathology.org/upcfbih
  • Peer-reviewer (since 2011): >50 biomedical journals including BMC Cancer, BMC Clinical Pathology, Journal of Clinical Pathology, Histopathology, Pathology - Research and Practice, APMIS, Cancer Letters, Expert Review of Molecular Diagnostics, PLoS One, Oncotarget, Future Oncology, Targeted Oncology, International Journal of Surgical Pathology, World Journal of Surgical Oncology, Diagnostic Pathology, Expert Opinion on Biological Therapy, Journal of ImmunoTherapy of Cancer, Frontiers in Bioscience, Molecular Medicine, Journal of International Medical Research, Diagnostic Cytopathology, Journal of Obstetrics and Gynaecology, Cell Biology and Toxicology, OncoTargets and Therapy, Clinical Epidemiology, Chinese Journal of Cancer Research, Journal of Drug Targeting, Journal of Experimental & Clinical Cancer Research, Personalized Medicine, Cancer Cell International, Molecular Oncology, Signal Transduction and Targeted Therapy, Frontiers in Oncology, Cancer Management and Research, Heliyon, Oxford Medical Case Reports, Journal of Cancer Research and Therapeutics, Cancers, Gene, Tumor Biology, Medical Science Monitor, Frontiers of Medicine (Springer), Clinical Case Reports, Journal of Pathology, Clinical Cancer Investigation, Journal for Immunotherapy of Cancer, Clinical Breast Cancer, DNA and Cell Biology, Applied Immunohistochemistry and Molecular Morphology, Case Reports in Oncological Medicine, Current Molecular Medicine, Clinical Medicine Insights: Oncology, Oncology Letters, Acta Medica Croatica, Acta Medica Academica, Nanomedicine, European Journal of Pharmacology, International Journal of Molecular Sciences, Cancer Medicine, Acta Biochimica Polonica, Chronic Disease and Translational Medicine, Immunotherapy, Molecular Biology Reports.

Editorial boards

Teaching skills

  • Undergraduate medical students courses in general and systemic pathology including:
  • Genetic and developmental diseases
  • Fundamental principles of cancer biology and pathology
  • Lung and mediastinal pathology
  • Endocrine pathology
  • Breast pathology
  • Gynecological pathology
  • Genitourinary pathology

Fellowships and Awards

  • Breast training program in a European Breast Unit (sponsored by the European Society of Mastology), City Hospital Nottingham, United Kingdom (2008)
  • American Cancer Society international fellowship for beginning investigators (ACSBI) (2008)
  • UICC Lifetime Fellow (2010)
  • Visiting Fellowship in Breast Pathology, Guy's and St. Thomas' NHS Foundation Trust/King's College London (2012)
  • Post-doc Fellowship at the University of Turin (Italy), Erasmus University Rotterdam, Netherlands (2012)
  • Award as the most productive PhD student at the Zagreb University School of Medicine (2012)
  • President of the Association of Pathologists and Cytologists of Federation of Bosnia and Herzegovina (2015-2017)
  • "The rising stars in pathology", award by the Pathologist (2016)
  • Member of the Council for Science and Art, University of Sarajevo (2016-2017)

Memberships

  • European Association for Cancer Research (2005-)
  • European Society of Pathology (ESP) (2006-)
  • Clinical Genetic Society of Croatia (2007-)
  • United States & Canadian Academy of Pathology (USCAP) (2010-)
  • Fellow and Life Member of International Union Against Cancer (UICC) (2010-)
  • The European Network of Uropathology (2011-)
  • ESP Working Group for Breast Pathology (2011-)
  • World Association of Medical Editors (WAME) (2015-)
  • Council of Science Editors (2015-)
  • Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina (2015-)
  • Association of Pathologists and Cytologists of Federation of Bosnia and Herzegovina (2015-)
  • COPE (Committee on Publication Ethics) (2016-)

Selected Recent Publications/Abstracts (Peer-reviewed and SCI Indexed)

  1. Bilalović N, Vranić S, Bašić H, Tatarević A, Selak I. Immunohistochemical evaluation of cyclin D1 expression in breast cancer. Croat Med J 2005;46:382-88.
  2. Vranić S, Kapur L, Fočo F, Bilalović N, Hainaut P. The first case of Li-Fraumeni syndrome in Bosnia and Herzegovina: Case report. Pathologica 2006;98:156-59.
  3. Vranić S, Bilalović N, Lee LMJ, Krušlin B, Lilleberg S, Gatalica Z. PIK3CA and PTEN mutations in adenoid cystic carcinoma of the breast metastatic to kidney. Hum Pathol 2007;38:1425-31.
  4. Silva E, Gatalica Z, Snyder C, Vranic S, Lynch JF, Lynch HT. Management of Hereditary Breast-Ovarian Cancer Syndrome. Part II. Breast J 2008;14:14-24.
  5. Vranic S, Caughron SK, Djuricic S, et al. Hamartomas, teratomas and teratocarcino-sarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature. BMC Ear Throat Nose Dis 2008;8:8.
  6. Gatalica Z, Lilleberg SL, Vranic S, Eyzaguirre E, Orihuela E, Velagaleti G. Novel intronic germ-line FLCN gene mutation in a patient with multiple ipsilateral renal neoplasms. Hum Pathol 2009;40:1813-19.
  7. Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LMJ, Adegboyega P, Hagenkord J, Gatalica Z. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010;23:644-53.
  8. Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LMJ, Gatalica Z. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently over-express EGFR protein without EGFR gene amplification. Hum Pathol 2010;41:1617-23.
  9. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 2011;117:48-53.
  10. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011;30:770-80.
  11. Vranic S, Gatalica Z, Frkovic-Grazio S, Deng H, Lee LMJ, Gurjeva O, Wang ZY. ER-α36 a novel isoform of ER-α66 is commonly over-expressed in apocrine and adenoid cystic carcinoma of the breast. J Clin Pathol 2011;64:54-7.
  12. Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z. IMP3, a proposed novel basal phenotype marker, is commonly over-expressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol 2011;19:413-16.
  13. Vranic S, Gatalica Z, Wang ZY. Update on molecular profile of the MDA-MB-453 cell line, a a model for apocrine carcinoma studies. Oncol Lett 2011;2:1131-37.
  14. Vranic S, Frkovic-Grazio S, Bilalovic N, Gatalica Z. Angiogenesis in adenoid cystic carcinoma of the breast. Virchows Arch 2011;459:377-82.
  15. Foco F, Bilalovic N, Vranic S, Serdarevic F, Ramovic I, Imamovic E. Peritumoral expression of p53 protein in oral carcinoma. Coll Antropol 2012;36(suppl.2):129-32.
  16. Dotlic S, Vranic S, Jakovljevic G, Ilic I, Kardum-Paro MM, Dojcinov SD. Neonatal hyperimmune T-cell reaction mimicking T-cell non-Hodgkin lymphoma following BCG and Hepatitis B co-vaccination. Virchows Arch 2012; 461:601-5.
  17. Vranic S, Bender R, Palazzo J, Gatalica. Z. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol 2013;44:301-9.
  18. Vranic S, Hes O, Grossmann P, Gatalica Z. Low frequency of HIF-alpha over-expression in germ cell tumors of the testis. Appl Immunohistochem Mol Morphol 2013;21:168-72.
  19. Skenderi F, Krakonja F, Vranic S. Infarcted fibroadenoma of the breast: Report of two cases with review of the literature. Diagn Pathol 2013;8(1):38.
  20. Vranic S, Schmitt F, Sapino A, Costa JL, Castro M, Reddy S, Gatalica Z. Apocrine carcinoma of the breast: A comprehensive review. Histol Histopathol 2013;28:1393-1409.
  21. Vranic S, Castellano I, Marchio C, Botta C, Tondat F, diCelle PF, Scalzo MS, Sapino A. Immunohistochemical and molecular profiling of invasive apocrine carcinoma of the breast. Virchows Arch 2013;463(2):250-1.
  22. Costa LJ, Justino A, Gomes M, Alvarenga CA, Gerhard R, Vranic S, Gatalica Z, Machado JC, Schmitt F. Comprehensive genetic characterization of apocrine lesions of the breast. Cancer Res 2013;73(8):2013.
  23. Zmijanac J, Fabijanovic D, Skrtic A, Vranic S, Nikuseva Martic T, Serman L. Immunohistochemical expression of Sfrp1 and Sfrp3 proteins in normal and malignant reproductive tissues of rats and humans. Appl Immunohistochem Mol Morphol 2014;22:681-7.
  24. Serman L, Nikuseva-Martic T, Vranic S. T-cell factor 1 expression in germ cell tumors with trophoblastic differentiation. Pathol Int 2014;64:86-7.
  25. Dotlic S, Gatalica Z, Wen W, Ghazalpour A, Bridge JA, Mangham C, Babic D, Zekan J, Vranic S. Extraskeletal myxoid chondrosarcoma of the vulva with PLAG1 gene activation: Molecular genetic characterization of two cases. Appl Immunohistochem Mol Morphol 2014;22:537-42.
  26. Millis S, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang N. Molecular profiling of infiltrating urothelial carcinoma of the bladder. J Clin Oncol 2014;32(suppl.4):Abstr 311; Note: ASCO Genitourinary Cancers Symposium 2014.
  27. Gatalica Z, Snydder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O. Programmed cell death (PD-1) and its ligand (PD-L1) expression in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014;23:2965-70.
  28. Gatalica Z, Millis ZS, Vranic S, Bender R, Basu G, Voss A, Von Hoff D. Comprehensive tumor profiling identifies numberous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases. Oncotarget 2014;5:12440-7.
  29. Marusic Z, Kos M, Labinec-Peteh L, Vranic S, Luzar B. Cystic fibroepithelioma of Pinkus: Report of two new cases and review of cystic changes in classical fibroepithelioma of Pinkus. Bosn J Basic Med Sci 2014;14:205-8.
  30. Silva E, Gatalica, Vranic S, Basu G, Sandeep KR, Voss A. Molecular profiling of angiosarcomas of the breast. Ann Oncol 2014;25(suppl.4):iv494-iv510.
  31. Gatalica Z, Vranic S, Basu G, Lynch HT. Thymidylate Synthase over-expression underlies the observed lack of 5-FU therapy benefit for MSI-H colorectal cancer. Ann Oncol 2014;25(suppl.4):iv167-iv209.
  32. Gatalica Z, Ghazalpour A, Bender R, Vranic S, Basu G, Millis S, Voss A. Biomarkers of targeted therapies in phyllodes sarcomas of the breast. Ann Oncol 2014;25(suppl.4):iv110-iv115.
  33. Kos M, Vranic S, Djuricic S, Hes O, Basu G, Gatalica Z. Renal cell carcinomas in pediatric population: A comprehensive molecular profiling of 7 cases. Virchows Arch 2014; 465(suppl.1):S195.
  34. Kovari B, Vranic S, Kocsis L, Sapino A, Cserni G. Growth hormone releasing hormone receptor (GHRH-R) expression in various types of apocrine epithelial lesions - apocrine breast carcinomas and cutaneous tumors with apocrine features. Virchows Arch 2014; 465(suppl.1):S102.
  35. Ghazalpour A, Kiss O, Vranic S, Kulka J, Gatalica Z. Identification of differentially expressed miRNAs and their targets in adenoid cystic carcinoma of the breast.  Virchows Arch 2014;465(suppl.1):S322.
  36. Kiss O, Ghazalpour A, Vranic S, Kulka J, Gatalica Z. Cyclin D1 and Bcl-2 expression in breast- and salivary gland-derived adenoid cystic carcinoma: An immunohistochemical study. Virchows Arch 2014; 465(suppl.1):S118. 
  37. Peckova K, Martinek P, Vranic S,  Kokoskova B, Hora M, Michal M, Hes O. Aggressive and non-aggressive translocation t(6;11) renal cell carcinoma: Comparative study of 6 cases. Virchows Arch 2014; 465(suppl.1):S160.
  38. Skenderi F, Ulamec M, Vranic S, Bilalovic N, Peckova K, Rotterova P, Kokoskova B, Branzovsky J, Michal M, Hes O. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: Morphological and immunohistohemical study. Pathology 2014;46(S2):135-6. 
  39. Peckova K, Vanecek K, Martinek P, Spagnolo D, Kuroda N, Brunelli M, Vranic S, Djuricic S, Rotterova P, Daum O, Kokoskova B, Vesela P, Pivovarcikova K, Bauleth K, Dubova M, Kalusova K, Hora M, Michal M, Hes O. Aggressive and non-aggressive translocation t(6;11) renal cell carcinoma: Comparative study of 6 cases and review of the literature. Ann Diagn Pathol 2014;18:351-7.
  40. Serman L, Nikuseva Martic T, Serman A, Vranic S. Epigenetic alterations of the Wnt signaling pathway in cancer. Bosn J Basic Med Sci 2014;14:191-4.
  41. Millis S, Bryant D, Basu G, Bender R, Vranic S, Gatalica Z, Vogelzang NJ. Theranostic molecular profiling of infiltrating urothelial carcinoma of the bladder. Clin Genitourin Cancer 2015;13:e37-49. 
  42. Silva E, Gatalica Z, Vranic S, Basu G, Sandeep KR, Voss A. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with Sunitinib: A case report and review of 16 additional cases with molecular profiling. Breast J 2015;21:205-7.
  43. Peckova K, Martinek P, Suster S, Sperga S, Montiel DP, Daum O, Rotterova P, Kalusova K, Hora M, Pivovarcikova K, Rychly B, Vranic S, Davidson W, Vodicka J, Michal M, Hes O. Mucinous spindle and tubular renal cell carcinoma: Analysis of chromosal aberration pattern of low grade, high grade, and overlapping morphologic variant with papillary renal cell carcinoma. Ann Diagn Pathol 2015;19;226-31. 
  44. Gatalica Z, Bilalovic N, Palazzo J, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff DD, Arceci RJ. Disseminated histiocytoses: Biomarkers beyond BRAFV600E. J Clin Oncol 2015;33(suppl. abstr. e22207).
  45. Gatalica Z, Vijayvergia N, Vranic S, Xiu J, Reddy S, Lynch HT, El-Deiry WS. Therapeutic biomarker differences between MSI-H and MSS colorectal cancers. J Clin Oncol 2015;33(suppl. abstr. 3597).
  46. Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci DJ. Disseminated histiocytoses biomarkers beyond BRAFV600E: Frequent expression of PD-L1. Oncotarget 2015;6(23):19819-25.
  47. Cesarec S, Kirgin MS, Skenderi F, Ulamec M,  Stimac G, Chikha A, Vranic S, Kruslin B. Sarcomatoid variant of urothelial carcinoma of the urinary bladder. A study of 27 cases. Virchows Arch 2015;467(suppl.1):S263.
  48. Vranic S, Marchio C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, Verdun di Cantogno L, Gugliotta P, Tondat F, Francia di Celle P, Mariani S, Gatalica Z, Sapino A. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. Hum Pathol 2015;46:1350-9.
  49. Skenderi F, Vranic S, Damjanov I. Programmed cell death in diagnostic histopathology. Int J Dev Biol 2015;59:149-58.
  50. Gatalica Z, Burnett K, Bender R, Feldman R, Vranic S, Reddy S. BRAF mutations are potentially targetable alterations in a wide variety of solid tumors. Eur J Cancer 2015; 50(suppl.3): S31.(Abstract #213, ECCO/ESMO 2015). 
  51. Millis S, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA. Predictive biomarker profiling of >6,000 breast cancer patients shows heterogeneity in TNBC with treatment implications. Clin Breast Cancer 2015;15:473-81.
  52. Kiss O, Tokes AM, Vranic S, Gatalica Z, Szilagyi A, Lippai N, Vass L, Jackel M, Udvarhelyi N, Szasz AM, Kulka J. Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands. Virchows Arch 2015;467:551-62.
  53. Gatalica Z, Bilalovic N, Vranic S, Arguello D, Reddy S, Gosh N. PD-1 and PD-L1 expression in lymphomas. Blood 2015;126:3899. (Annual meeting, American Society of Hematology 2015). 
  54. Damjanov I, Vranic S, Skenderi F. Does everything a surgeon takes out have to be seen by a pathologist? A review of the current pathology practice. Virchows Arch 2016;468:69-74.
  55. Skenderi F, Ulamec M, Vranic S, Bilalovic N, Peckova N, Rotterova P, Kokoskova B, Branzovsky J, Michal M, Hes O. Cystic renal oncocytoma and tubulocystic renal cell carcinoma. Morphological and immunohistochemical study. Appl Immunohistochem Mol Morphol 2016;24(2):112-9.
  56. Lukenda A, Dotlic S, Vukojevic N, Saric B, Vranic S, Zarkovic K. Expression and prognostic value of putative cancer stem cell markers CD117 and CD15 in choroidal and ciliary body melanoma. J Clin Pathol 2016;69:234-9
  57. Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S, Bovan NS. The reality of cancer treatment in a developing country: The effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol 2016;172(3):420-7.
  58. Gatalica Z, Vranic S, Ghazalpour A, Xiu J, Ocal I, McGill J, Bender RP, Discianno E, Schlum A, Sanati S, Palazzo J, Reddy S, Pockaj B. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. Oncotarget 2016;7(2):1707-16.
  59. Gatalica Z, Vranic S, Ghazalpour A, Xiu J, Ocal IT, McGill J, Bender R, Disciano E, Sanati S, Reddy S, Pockaj B. Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. Cancer Res 2016;76(4 Suppl.):Abstract nr P4-09-19.
  60. Gatalica Z, Vranic S, Rose I, Teresi P, Feldman R, Bender RP. Concordance of anti-BRAF p. V600E immunohistochemistry with BRAF gene sequence in solid tumors carrying diverse BRAF mutations. Mod Pathol 2016;29(suppl.2):454A (Abstract#1797).
  61. Redzepagic J, Skenderi F, Bajrovic J, Beslagic V, Ibisevic N, Vranic S. Low grade malignant peripheral nerve sheath tumor of the breast: A report of the first case and literature review. APMIS 2016;124:428-30. 
  62. Feldman R, Gatalica Z, Vranic S, Bender R, Reddy S, Ghazalpour A. Caveolin-1: Beyond a marker for basal-like breast cancers. Cancer Res 2016;76(14 Suppl.):3928. (AACR Annual Meeting 2016, New Orleans, Louisiana, April 2016).
  63. Arguello D, Gatalica Z, Vranic S, Reddy S, VanderWalde A. Analysis of MET-amplified solid tumors using chromogenic in situ hybridization (CISH). Cancer Res 2016;76(14 Suppl.):396. (AACR Annual Meeting 2016, New Orleans, Louisiana, April 2016).
  64. Ulamec M, Skenderi F, Trpkov K, Kruslin B, Vranic S, Bulimbasic S, Trivunic S, Perez-Montiel D, Peckova K, Pivovarcikova K, Ondic O, Daum D, Rotterova P, Dusek M, Hora M, Michal M, Hes O. Solid papillary renal cell carcinoma: Clinicopathologic, morphologic and immunohistochemical analysis of 10 cases and review of the literature. Ann Diagn Pathol 2016;23:51-7.
  65. Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S. Microsatellite instability high (MSI-H) colorectal carcinoma: A brief review of predictive markers in the era of personalized medicine. Fam Cancer 2016;15:405-12.
  66. Damjanov I, Skenderi F, Vranic S. Mammary Analogue Secretory Carcinoma (MASC) of the salivary gland: A new tumor entity. Bosn J Basic Med Sci 2016;16:237-8.
  67. Jurcic P, Kruslin B, Gatalica Z, Sanati S, Vranic S. Breast carcinoma with neuroendocrine features: a brief review. Endocr oncol metab 2016;2(2):138-45.
  68. Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, Vranic S, Kopric D, Iljazovic E, Todorovic Barbuscia J, Ibisevic N, Kurtovic S. Long-term outcome of GIST patients with delayed imatinib therapy. J Clin Oncol 2016;34(suppl; abstr e22518).
  69. Fabijanovic D, Zunic I, Nikuseva Martic T, Skenderi F, Serman L, Vranic S. The expression of SFRP1, SFRP3, DVL1 and DVL2 proteins in germ cell tumors of the testis. APMIS 2016;124:942-9.
  70. Fabijanovic D, Zunic I, Nikuseva Martic T, Skenderi F, Serman L, Vranic S. The members of Wnt pathway SFRP1, SFRP3 and DVL1 are downregulated in testicular germ cell tumors. Virchows Arch 2016;469(suppl.1):S218-9.
  71. Skenderi F, Ibisevic N, Topcagic J, Bilalovic N, Vranic S. Breast cancer incidence, demographic, and pathological characteristics in Bosnia and Herzegovina. Virchows Arch 2016;469(suppl.1):S58.
  72. Skenderi F, Ulamec M, Vranic S, Michal M, Hes O. Warthin-like papillary renal cell carcinoma with prominent lymphocytic infiltrate: Morphologic and immunohistochemical study. Virchows Arch 2016;469(suppl.1):S14.
  73. Ibisevic N, Skenderi F, Chikha A, Bilalovic N, Vranic S. Cervical cancer incidence, demographic and pathologic characteristics in Bosnia and Herzegovina. Virchows Arch 2016;469(suppl.1):S289.
  74. Chikha A, Ibisevic N, Skenderi F, Bilalovic N, Kulovac B, Selimović M, Vranic S. Spermatocytic seminoma: Report of three cases. Virchows Arch 2016; 469(suppl.1):S236.
  75. Vranic S, Jin J, Kimbrough J, Ghosh N, Bilalovic N, Arguello D, Veloso Y, Hendershot T, Dizdarevic A, Reddy S, Gatalica Z. PD-L1 status in refractory lymphomas. Ann Oncol 2016;27(suppl.6):vi317-8 (ESMO 2016, Copenhagen).
  76. Gatalica Z, Ghazalpur A, Swensen J, Bender R, Vranic S, Feldman R, Reddy S. Molecular profiling of locally advanced/metastatic olfactory  neuroblastomas (esthesioneuroblastomas). Ann Oncol;2016;27(suppl.6):vi334 (ESMO 2016, Copenhagen).
  77. Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, Veloso Y, Dizdarevic A, Gatalica Z. PD-L1 status in refractory lymphomas. PLOS One 2016;11(11):e0166266.
  78. Karin V, Kakarigi L, Skrtic A, Nikuseva Martic T, Ibisevic N, Skenderi F, Vranic S, Serman L. Sonic Hedgehog proteins are overexpressed in high-grade serous ovarian carcinomas. Libri Oncologici 2016;44(1):38. 
  79. Skenderi F, Chikha A, Ibisevic N, Tatarevic-Suko A, Kantardzic N, Vranic S. Skeletal muscle metastases of the cervical carcinoma: Report of two cases with literature review. Int J Gynecol Pathol 2017;36:95-100.
  80. Upasana J, Vranic S, Swensen J, Feldman R, Chen S, Xiao N, Reddy S, Palazzo J, Gatalica Z. Comprehensive profiling of metaplastic breast carcinomas reveales frequent over-expression of PD-L1. J Clin Pathol 2017;70:255-9.
  81. Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci 2017;17:9-11.
  82. Skenderi F, Ulamec M, Vanecek T, Martinek P, Alaghehbandan R, Pane Foix M, Babankova I, Perez Montiel D, Alavarado-Cabrero I, Svajdler M, Dubinsky P, Cempirkova D, Pavlovsky M, Vranic S, Daum O, Ondic O, Pivovarcikova K, Michalova K, Hora M, Rotterova P, Stehlikova A, Michal M, Dusek M, Hes O. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases. Ann Diagn Pathol 2017;27:48-56.
  83. Gatalica Z, Feldman R, Ghazalpour A, Vranic S. Characterization of neuroendocrine breast carcinomas for biomarkers of therapeutic options. Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-27.
  84. Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DSM, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M,  Sakr W, Sheng S. An essential role of maspin in embryogenesis and tumor suppression. Cancer Res 2017;77(4):1-11.
  85. Michal M, Kazakov D, Agaimy A, Hosova M, Michalova K, Grossmann P, Steiner P, Skenderi F, Vranic S, Michal M. Whorling Cellular Perineurioma: A previously undescribed variant closely mimicking monophasic fibrous synovial sarcoma. Ann Diagn Pathol 2017;27:74-8.
  86. Senarathne J, Gates P, Vranic S, Gatalica Z. A comparative analysis of PD-L1 distribution in primary NSCLC and metastatic tumors to the lung. Mod Pathol 2017;30(supplement 2s):494A.
  87. Michal M, Kazakov DV, Agaimy A, Michalova K, Grossmann P, Skenderi F, Vranic S, Michal M. Whorling Cellular Perineurioma: An undescribed benign tumor mimicking monophasic fibrous synovial sarcoma. Mod Pathol 2017;30(supplement 2s):20A.
  88. Mahdi Z, Dzinic SH, Vranic S, Skenderi F, Sheng S, Beydoun R. Differential Expression and Subcellular Localization of Tumor Suppressor Maspin as a Diagnostic Marker in Gastroesophageal Junction Carcinoma and Its Precursors. Mod Pathol 2017;30(supplement 2s):185A.
  89. Kurtovic-Kozaric A, Kugic A, Hasic A, Beslija S, Ceric T, Pasic A, Vranic S, Kopric D, Iljazovic D, Todorovic Barbuscia J, Ibisevic N, Kurtovic S. The effects of delayed imatinib mesylate treatment on outcome in patients with GIST. Eur J Cancer 2017;78:118-21.
  90. Demirović A, Vranić S, Skenderi F, Perić Balja M, Ulamec M, Vučić M, Krušlin B. Primary neuroendocrine carcinoma of the breast: a diagnostic approach to the rare primary breast malignancy. Neuroendocrinology 2017;105(suppl.1):1-338. (Abstracts of the 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, March 8–10, 2017, Barcelona, Spain)
  91. Gatalica Z, Senarathne J, Vranic S. PD-L1 expression patterns in the metastatic tumors to the lung: a comparative study with the primary non-small cell lung cancer. Ann Oncol 2017;28(suppl.2):mdx094.003. (European Lung Cancer Conference 2017).
  92. Kurtovic-Kozaric A, Vranic S, Kurtovic S, Hasic A. Access to targeted cancer treatment modalities in developing world in the era of personalized medicine: Lessons from Bosnia. J Glob Oncol 2018;4:1-5. doi: 10.1200/JGO.2016.008698.
  93. Kővári B, Vranic S, Marchio C, Sapino A, Cserni G. The expression of growth hormone releasing hormone (GHRH) and its receptors in breast carcinomas with apocrine differentiation – further evidence of the presence of a GHRH pathway in these tumors. Hum Pathol 2017;64:164-70.
  94. Vranic S. Recent advances in molecular pathology of breast cancer. 26thLjudevit Jurak International Symposium on Comparative Pathology. Book of Abstracts, Zagreb, 2017, p.20.
  95. Kardum V, Karin V, Glibo M, Skrtic A, Nikuseva Martic T, Ibisevic N, Skenderi F, Vranic S, Serman L. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas. Ann Diagn Pathol 2017;31:45-9.
  96. Zmijanac Partl J, Karin V, Skrtic A, Nikuseva-Martic T, Serman A, Mlinarec J, Curkovic-Perica M, Vranic S, Serman L. Negative regulators of Wnt signaling pathway SFRP1 and SFRP3 expression in preterm and term pathologic placentas. J Matern Fetal Neonatal Med 2018;31:2971-9.
  97. Karin V, Kardum V, Glibo M, Skrtic A, Nikuseva Martic T, Ibisevic N, Skenderi F, Vranic S, Serman L. Methylation-associated silencing of SFRP1 gene in high-grade serous ovarian carcinomas. 10th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Dubrovnik, June 19-24, 2017.
  98. Kurtovic-Kozaric A, Kugic A, Hasica A, Ceric T, Vranic S, Djuran A, et al. Impact of CD117 Expression on the Survival of GIST Patients. 10th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine. Dubrovnik, June 19-24, 2017.
  99. Vranic S. Microsatellite instability status predicts response to anti-PD-1/PD-L1 therapy regardless the histotype: A comment on recent advances. Bosn J Basic Med Sci 2017;17(3):274-5.
  100. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, Vranic S. A Clinicopathologic Study of Invasive Apocrine Carcinoma of the Breast: A single center experience. Breast J 2018;24:1105-8.
  101. Imamovic D, Vranic S. Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4: A new avenue to enhance the therapeutic benefits of immune check point inhibitors. Ann Transl Med 2017;5(23):467.
  102. Vranic S, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z. Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast. Breast J 2019;25(1):175-6.
  103. Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, Vranic S. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. PLoS ONE 2018;13(1): e0191244.
  104. Senarathne W, Vranic S, Xiu J, Rose I, Gates P, Gatalica Z. Primary lung non-small cell carcinomas differ in the composition of the immune microenvironment from the carcinomas metastatic to the lungs. Ann Diagn Pathol 2018;33:62-8.
  105. Gatalica Z, Palazzo J, Sanati S, Florento E, Xiu J, Swensen J, Vranic S. Comprehensive molecular profiling of neuroendocrine breast carcinoma reveals biomarkers of targeted treatment. Mod Pathol 2018;31(suppl.2):61. (USCAP 2018).
  106. Vranic S, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z. Comprehensive molecular profiling of pleomorphic ductal carcinoma of the breast with theranostic implications. Mod Pathol 2018;31(suppl.2):112 (USCAP 2018).
  107. Karin V, Slavica M, Skrtic A, Vranic S, Serman L. Hedgehog signaling pathway status in serous ovarian carcinomas. Mod Pathol 2018;31(suppl.2):428-9. (USCAP 2018).
  108. Skoda AM, Simovic D, Karin V, Kardum V, Vranic S, Serman S. The role of the Hedgehog signaling pathway in cancer: A comprehensive review. Bosn J Basic Med Sci 2018;18(1):1-13.
  109. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, Vranic S. Clinicopathologic characteristics of invasive apocrine carcinoma of the breast: A single center experience from a country with limited resources. Eur J Cancer 2018;92(suppl.3):S24. (EBCC-11, Barcelona 2018).
  110. Gatalica Z, Xiu J, Swensen J, Vranic S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune check-point blockade therapy. Eur J Cancer 2018;94:179-86.
  111. Karin V, Skrtic A, Skenderi F, Ibisevic N, Vranic S, Serman L. The status of SHH and IHH in serous ovarian carcinomas. Ann Oncol 2018;31(suppl_3):mdy047.016. (TAT 2018 – Targeted Anticancer Therapies, Paris, March 2018).
  112. Bonfil DR, Friedman R, Vranic S, et al. Discoidin domain receptor 1 (DDR1): A potential suppressor of prostate cancer progression. Cancer Res 2018;78(13)(suppl.):1070. (https://doi.org/10.1158/1538-7445.AM2018-1070)
  113. Vranic S, Cyprian FS, Akhtar S, Al Moustafa AE. The role of Epstein-Barr virus (EBV) in cervical cancer: A brief update. Front Oncol 2018;8:113.
  114. Cyprian FS, Al-Farsi HF, Vranic S, Akhtar S, Al Moustafa AE. Epstein-Barr virus and human papillomaviruses interactions and their roles in the initiation of EMT and cancer progression: A brief review. Front Oncol 2018;8:111.
  115. Akhtar S, Cyprian FS, Vranic S, Al Moustafa AE. Epstein-Barr Virus in Gliomas: Cause, Association or Artefact? Fronti Oncol 2018;8:123.
  116. Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S. Is the time ready for molecular profiling in relapsed and refractory multiple myeloma patients? A comprehensive literature review. Int J Mol Sci 2018;19:2087; doi:10.3390/ijms19072087.
  117. Al-Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, Al Moustafa AE. Co-incidence of Epstein–Barr virus and high-risk human papillomaviruses in cervical cancer of Syrian women. Front Oncol 2018;8:250.
  118. Vranic S, Ghabreau L, Al-Thawadi H, Alkhalaf M, Al Moustafa AE. The frequency of Epstein-Barr virus and high-risk human papillomaviruses co-infection in cervical carcinoma samples of Syrian women. Abstractbook of Posters and Oral Presentations, XXXII Congress of the International Academy of Pathology, P-06, Abstract No. 053, Amman 2018
  119. AlAhmad YFM, Abdelhafez IHE, Cyprian FS, Skenderi F, Akhtar S, Vranic S. Predatory journals in pathology: A comprehensive assessment. Abstractbook of Posters and Oral Presenations, XXXII Congress of the International Academy of Pathology, FOP-08-1, Abstract No. 003, Amman, 2018.
  120. Chikha A, Ibisevic N, Skenderi F, Junuzovic D, Vranic S. A bilateral sex-cord stromal tumor of the testis. Report of the case. Abstractbook of Posters and Oral Presentations, XXXII Congress of the International Academy of Pathology, P-18, Abstract No. 10, Amman 2018.
  121. Gatalica Z, Xiu J, Swensen J, Maney T, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32:147-53.
  122. Sadek KW, Haik MY, Ashour AA, Aboulkassim T, Yasmeen A, Vranic S, Zeidan A, Al Moustafa AE. Water-pipe smoking promotes epithelial-mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways. Cancer Cell International 2018;18:180.
  123. Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J, Gatalica Z. Novel predictive biomarkers of targeted treatment for patients with neuroendocrine carcinoma of the breast. Clin Breast Cancer 2019;19:131-6.
  124. Terlević R, Perić Balja M, Tomas D, Krušlin B, Vranic S, Skenderi F. Demirović A. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Ann Diagn Pathol  2019;38:62-6..
  125. Bedri S, Sultan AA, Alkhalaf M, Al Moustafa AE, Vranic S. The status of Epstein-Barr virus in colorectal cancer: A brief review. Human Vaccines and Immunotherapeutics 2019;15:603-10. 
  126. AlAhmad YFM, Abdelhafez IHE, Cyprian FS, Skenderi F, Akhtar S, Vranic S. Predatory journals in pathology: A Critical Appraisal. Resubmitted, April 2019.
  127. Gatalica Z, Senarathne W, Vranic S, Pockaj BA. Profiling of metastatic carcinomas to the breast for the biomarkers of immuno-oncology therapy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-27.
  128. Karin-Kujundzic V, Kardum V, Skrtic A, Skenderi F, Vranic S, Serman L. Expression of Dishevelled family proteins DVL1, DVL2 and DVL3 in serous ovarian carcinomas. Proceedings of the 2nd Frankfurt Conference on Quality Control in Life Processes & 8th International p63/p73 Workshop, September 2-6, 2018, Proceedings, pp 112-3 (Poster P1-031).
  129. Zvizdic Z, Haxhija E, Chikha A, Vranic S, Milisic E, Jonuzi A. Laparoscopic extirpation of adrenal gland ganglioneuroma incidentally diagnosed after evaluation for alopecia areata patchy in an adolescent boy. Medical Principles and Practice 2019 March 22 Epub Ahead Print.
  130. Terlevic R, Perić Balja M, Tomas D, Kruslin B, Vranic S, Skenderi F, Demirovic A. Somatostatin receptor expression in neuroendocrine breast cancer. Virchows Arch 2018;473(suppl.1):30. (30th European Congress of Pathology, Bilbao 2018)
  131. Dzinic SH, Mahdi Z ,Bernardo MM, Vranic S, Beydoun H, Nahra N, Alijagic A, Harajli D, Pang A, Saliganan DM, Rahman AM, Latchmansingh KA, Raval K, Skenderi F, Hasanbegovic B, Dyson G, Beydoun R, Sheng S. Maspin Differential Expression Pattern as a Marker for Targeted Screening of Gastroesophageal Junction Adenocarcinoma. PLoS One 2019;14(4):e0215089. doi: 10.1371/journal.pone.0215089. eCollection 2019.
  132. Zvizdic Z, Jonuzi A, Djuran A, Vranic S. Gastric Necrosis and Perforation Following Massive Acute Gastric Dilatation in an Adolescent Girl: A Rare Cause of Acute Abdomen. Front Surg 2019;6:3. https://www.frontiersin.org/articles/10.3389/fsurg.2019.00003/abstract.
  133. Mardekian S, Senarathne W, Feldman F, Florento E, Swensen J, Vranic S, Gatalica Z. Comprehensive molecular profiling of salivary duct carcinomas. Mod Pathol 2019;32(suppl.2):15. (USCAP 2019).
  134. Zvizdic Z, Milisic E, Chikha A, Sefic I, Dzananovic A, Vranic S. Encysted Hydrocele of the Canal of Nuck in an 11-Month-Old-Child with a Past History of Duodenal Atresia and Arnold-Chiari Malformation: A case report. Medicine (Baltimore) 2019 Jan;98(4):e14232. doi: 10.1097/MD.0000000000014232.
  135. Gatalica Z, Senarathne W, Poorman K, Vranic S, Pockaj B. Targeted therapy and immuno-oncology biomarkers in cancers metastatic to the breast. To be resubmitted, April 2019.
  136. Vranic S, Sadek KW, Haik MY, Ashour AA, Al Moustafa AA. Water-pipe smoking enhances the progression and invasiveness of human breast cancer cells. Cancer Res 2019, suppl., in press (American Association for Cancer Research (AACR) Annual Meeting 2019).
  137. Al-Qahdi SS, Alzohari N, Alsaid AY, Ashour AA, Aboulkassim T, Vranic S, Al Moustafa AE, Khalil A. Teucrium Polium Plant Extract Provokes Substantial Cytotoxicity at the Early Stage of Embryonic Development. Bosn J Basic Med Sci 2019;19(1):67-71.
  138. Imamovic D, Bilalovic N, Skenderi F, Beslagic V, Ceric T, Hasanbegovic B, Beslija S, Vranic S. Reply Letter to the Editor. Breast J 2019;25(3):569.https://doi.org/10.1111/tbj.13284 
  139. Mardekian S, Vranic S, Swensen J, Senarathne J, Feldman R, Gatalica Z. Comprehensive molecular profiling of salivary duct carcinoma. To be submitted, April 2019.
  140. Gatalica S, Vranic S, Stafford P, Skenderi F, Swensen J, Xiu J, Spetzler D. Spindle cell carcinoma of the breast: rare cancer with potentially targetable biomarkers. Ann Oncol 2019;30(suppl.3):mdz095.057, https://doi.org/10.1093/annonc/mdz095.057
  141. Gupta IR, Sareyeldin RM, Al-Hashimi I, Al-Thawadi H, Vranic S, Al Moustafa AE. Progression of the triple negative breast cancer profile from gene to microRNA: an overview. Cancers (Basel) 2019;11(3):363. doi: 10.3390/cancers11030363
  142. Cyprian FS, Akhtar S, Gatalica Z, Vranic S. Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy:  A new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci 2019 Mar 27 Epub Ahead Print.
  143. Vranic S. Letter to Editor/Comment on the metaplastic carcinoma study. Breast J 2019, in press.
  144. Cubro H, Cengic V, Burina N, Kravic Z, Beciragic E, Vranic S. Appendiceal Mucocele Presenting as an Exacerbated Chronic Tubo-ovarian Abscess: A Case Report and Comprehensive Literature Review. Submitted, February 2019.
  145. Karin-Kujundzic V, Kardum V, Sola IM, Paic F, Skrtic A, Skenderi F, Serman S, Nikuseva-Martic N, Vranic S, Serman L. Could difference between trophoblast and cancer be more dishevelled? Resubmitted, Cells, May 2019.
  146. Sareyeldin RM, Gupta I, Al-Hashimi I, Al-Thawadi HA, Al Farsi H, Vranic S, Al Moustafa AE. Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. Cancers 2019;11(5):646.  doi: 10.3390/cancers11050646
  147. Vranic S, Arguello D, Contreras E, Cimic A, Gatalica Z. Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix. Submitted to ESMO 2019.
  148. Karin-Kujundzic V, Sola IM, Predavec N, Potkonjak A, Somen E, Mioc P, Serman A, Vranic S, Serman L. Epigenetic biomarkers of trophoblast and cancer cells invasion – diagnostic approaches in precision medicine. To be submitted (Frontiers in Genetics), May 2019.
  149. Mioc P, Karin Kujundzic V, Matijevic R, Skrtic A, Vranic S, Serman L. Smoothened protein expression and promoter methylation status in serous ovarian carcinomas. Submitted to ESGO, Athens November 2019.
  150. Beslija S, Ceric T, Hasanbegovic B, Skenderi F, Alidzanovic J, Kopric D, Marijanovic I, Mekic-Abazovic A, Šišic I, Hammami M, Pasic A, Rasic A, Kapisazovic E, Vranic S. Effects of delayed initiation of adjuvant trastuzumab for non-metastatic, Her2 positive breast cancer in a limited resources setting: ML25232 study final results. Submitted to ESMO 2019.

 Books/chapters

  1. Damjanov I, Vranic S, Skenderi F. Review of Gynecologic and Breast Pathology. Jaypee Brother Medical Publishers (P) Ltd. 2017, link: https://www.amazon.com/Review-Gynecologic-Breast-Pathology-Damjanov/dp/9352700473/ref=sr_1_1?ie=UTF8&qid=1506668227&sr=8-1&keywords=review+of+gynecologic+and+breast+pathology)
  2. Vranic S, Gatalica Z. Apocrine Carcinoma. Pathology Encyclopedia: Breast Pathology. Springer, 2018, link: https://link.springer.com/referenceworkentry/10.1007/978-3-319-28845-1_4693-1
  3. Gatalica Z, Feldman R, Vranic S, Spetzler D. Immunohistochemistry-enabled Precision Medicine. In: D. Von Hoff and H. Han (eds.), Precision Medicine in Cancer Therapy, Cancer Treatment and Research 178, 2019 (in press) https://doi.org/10.1007/978-3-030-16391-4_4
  4. Provenzano E, Gatalica Z, Vranic S. Carcinoma with apocrine differentiation. WHO Classification of Tumours 5th Edition - Tumours of the Breast. IARC, Lyon, 2019, in press.

Other articles

  1. Vranić, S. Topoisomerase II alpha (TOP2A). PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/stainstop2a.html.
  2. Vranic S. The School of Life: A collaboration between Britain and Bosnia – the Bryan Warren School of Pathology – is bringing education to trainees with limited access (2017), https://thepathologist.com/outside-the-lab/the-school-of-life 
  3. AlAhmad YFM, Abdelhafez IHE, Skenderi F, Vranic S. When progress becomes predation. The Pathologist 2019, https://thepathologist.com/outside-the-lab/when-progress-becomes-predation  

 Updated: May 15, 2019

            

Newsletter

Sign up for news from our website (announcements, availability of program and course materials; 2-5 emails per year).

Links

Bosnian Journal of Basic Medical Scienceslogopathoutlines